Introduction {#sec1-1}
============

Systemic Lupus Erythematosus (SLE) is one of the threatening autoimmune diseases that impend global health. The prevalence of SLE in the Asia-Pacific Region is 4.3-45.3 per 100,000 populations. Meanwhile, the prevalence of SLE in Indonesia is 0.5%, and the prevalence is escalating from year to year. There are 16.000 new SLE cases in the United States. This shows the number of new SLE cases is very significant. The cases of SLE require solemn emphasis from the pathophysiological aspects to a comprehensive therapeutic approach \[[@ref1]\].

SLE is a prototype of an autoimmune disorder characterised by antibody production towards components of the cell nucleus. The pathological conditions found in SLE patients are related to the inflammatory process, vasculitis, immune complex deposition and vasculopathy. The inflammatory process is the main pathological condition in SLE disorders \[[@ref2]\]. SLE begins with the formation of antibodies against the cell components of the individual itself, and Anti-double Stranded DNA (ds-DNA) is found in 95% of SLE cases.

The presence of ds-DNA is triggered by an increase in the B cell population, due to a decrease in the production of T cells, triggered by the production of IL-2. Increased IL-2 will promote the activation of Th-17 cells to produce IL-17. This condition will activate the inflammatory cascade, which is mediated by interleukin-1 (IL-1), IL-6 and Tumor Necrosis Factor-Alpha (TNF-α), which are responsible for the damage in various target organs and eventually will lead to target organ failure \[[@ref3]\].

Vitamin D is a steroid hormone playing a role in the regulation of cell growth, proliferation, apoptosis and regulation of the immune system. Vitamin D deficiency is one of the clinical conditions that further aggravate clinical SLE. Decreasing vitamin D levels is a common feature in SLE patients. Administration of immunosuppressant drugs (glucocorticoids) will trigger a decrease in vitamin D levels. Nevertheless the drug is the standard drug consumed by SLE patients. Vitamin D has the capacity in suppressing the immune response so that it will suppress inflammatory cascade \[[@ref4]\]. Vitamin D supplementation was able to optimally demote clinical problems in SLE patients \[[@ref5]\]. Therefore, vitamin D supplementation in SLE patients becomes strategic management.

Exploration of the vitamin D source modality is a strategic step for SLE management. Seluang fish (*Rasbora spp*.) is an endemic freshwater fish in South Sumatra, Indonesia. Seluang fish is the first level consumer in its food chain. As a first level consumer, it is safe from the accumulation of heavy metal contamination commonly found in top consumer fish. It is rich in oil that lines up the fish body. Previous studies showed that Seluang fish oil contained vitamin D (cholecalciferol) in the amount of 2043.34 IU/mL \[[@ref6]\]. With a massive vitamin D content, Seluang fish oil possesses the potential to be further investigated regarding its efficacy in SLE cases.

This study aimed to assess the efficacy of Seluang fish oil against proinflammatory cytokines (IL-1, IL-6, IL-17), serum Vitamin D levels, and MEX-SLEDAI clinical scores in SLE patients.

Material and Methods {#sec1-2}
====================

Subjects {#sec2-1}
--------

A randomised, double-blind, clinical trial study design was conducted. This study was conducted in the Rheumatology Outpatient Internal Medicine Department, Dr Moh. Hoesin General Hospital Palembang, South Sumatra, Indonesia. This study was by the Declaration of Helsinki of the World Medical Association and had received ethical approval by the Ethics Committee Faculty of Medicine, Universitas Sriwijaya, Dr Moh Hoesin General Hospital Palembang. Informed consent was done for all study subjects. The subjects of this study were 32 patients who met the criteria of American College of Rheumatology (ACR) 1997 classification, consisting of 16 SLE subjects who were treated with 500 uL Seluang fish oil capsules, one capsule per day, for 90 days and 16 SLE subjects who received placebo capsules. Study subjects were between 15-50 years, with no comorbidities or severe clinical conditions.

Measurement of proinflammatory cytokines and vitamin D levels {#sec2-2}
-------------------------------------------------------------

Three ml blood was withdrawn from each study subject, which was then inserted into the EDTA tube, then centrifuged at a speed of 5000 rpm for 10 minutes. The supernatant was obtained and stored at -20°C. Measurement of Vitamin D, IL-1, IL-6 and IL-17 levels was performed with Enzyme-linked Immunosorbent Assay (ELISA) technique Cloud-Clone (Cloud-Clone Corp., Texas, USA), by the work protocol issued by the manufacturer.

Clinical assessment of SLE {#sec2-3}
--------------------------

Clinical assessment of SLE was performed with the Systemic Lupus Erythematosus Disease Activity Index scoring system (SLEDAI) using data from medical records and laboratory findings. This scoring consisted of 24 items with a total score of 0-105.

Statistical analysis {#sec2-4}
--------------------

Data analysis was carried out using SPSS 24.0 software (SPSS Inc., Chicago, USA). Data were presented in the form of mean ± SD. Bivariate analysis, T-test, was conducted to analyse mean differences between the treatment and control groups. Statistical significance was of p-value \< 0.05.

Results {#sec1-3}
=======

[Table 1](#T1){ref-type="table"} exhibited that the clinical conditions of the study subjects between the treatment group and the control group were not statistically different. The subjects showed the equality of clinical conditions in SLE so that the possibility of bias in this study could be prevented.

###### 

Baseline Characteristics of Study Subjects

  Characteristics             Treatment         Placebo           P-value
  --------------------------- ----------------- ----------------- ----------------------------------------
  Age (years)                 30.31 ± 9.32      26.75 ± 8.96      0.227 [\*](#t1f1){ref-type="table-fn"}
  Duration of SLE (months)    18.63 ±13.54      21.09 ± 4.80      0.677[\*](#t1f1){ref-type="table-fn"}
  Haemoglobin (g/dL)          12.42 ± 1.89      11.69 ± 1.25      0.210[\*](#t1f1){ref-type="table-fn"}
  Leukocyte (x 10^3^) (/μL)   8.6 ± 3.28        8.69 ± 2.84       0.936[\*](#t1f1){ref-type="table-fn"}
  Platelet (x 10^3^) (/μL)    294.8 ± 56.34     330.81 ± 114.39   0.985[\*](#t1f1){ref-type="table-fn"}
  Blood sugar (mg/dL)         106.5 ± 33.08     105.38 ± 19.89    0.692[\*](#t1f1){ref-type="table-fn"}
  Ureum (mg/dL)               23.13 ± 7.81      25.5 ± 11.42      0.748[\*](#t1f1){ref-type="table-fn"}
  Creatinine (mg/dL)          0.693 ± 0.117     0.683 ± 0.286     0.126[\*](#t1f1){ref-type="table-fn"}
  SGOT (AST) (U/L)            20.31 ± 10.24     20.88 ± 7.35      0.416[\*](#t1f1){ref-type="table-fn"}
  SGPT (ALT) (U/L)            22.38 ± 15.66     22.00 ± 9.68      0.521[\*](#t1f1){ref-type="table-fn"}
  Calcium (mg/dL)             1.14 ± 0.08       1.17 ± 0.06       0.383[\*](#t1f1){ref-type="table-fn"}
  dsDNA (ng/mL)               434.4 ± 55.46     423.0 ± 52.64     0.318[\*](#t1f1){ref-type="table-fn"}
  Vitamin D (ng/mL)           44.81 ± 7.09      46.91 ± 9.16      0.474[\*](#t1f1){ref-type="table-fn"}
  IL-17 (pg/mL)               497.19 ± 148.34   515.57 ± 160.93   0.739[\*](#t1f1){ref-type="table-fn"}
  IL-1 (pg/mL)                69.81 ± 18.09     72.05 ± 19.62     0.739[\*](#t1f1){ref-type="table-fn"}
  IL-6 (pg/mL)                413.97 ± 95.09    425.75 ± 103.16   0.739[\*](#t1f1){ref-type="table-fn"}
  MEX SLEDAI                  3.31 ± 2.30       3.69 ± 2.41       0.656[\*](#t1f1){ref-type="table-fn"}

Unpaired T Test; p = 0.05.

The administration of Seluang fish oil was clinically able to show efficacy compared to placebo, which was assessed by the MEX SLEDAI score. Significant results were also shown by vitamin D levels, which exhibited that Seluang fish oil was able to increase serum vitamin D levels compared with placebo. Increased levels of vitamin D in the group receiving Seluang fish oil was followed by a decrease in inflammatory markers, namely a significant reduction in levels of IL-1, IL-6 and IL-17, compared to the placebo group ([Table 2](#T2){ref-type="table"}).

###### 

Proinflammatory Cytokines and Vitamin D Levels

  Measurement         Treatment        Placebo          P-value
  ------------------- ---------------- ---------------- ---------------------------------------
  Vitamin D (ng/mL)   89.81 ± 7.11     47.12 ± 3.16     0.005[\*](#t2f1){ref-type="table-fn"}
                                                        
  IL-17 (pg/mL)       245.31 ± 21.34   518.87 ± 65.33   0.001[\*](#t2f1){ref-type="table-fn"}
                                                        
  IL-1 (pg/mL)        39.21 ± 7.09     72.65 ± 18.71    0.003[\*](#t2f1){ref-type="table-fn"}
                                                        
  IL-6 (pg/mL)        213.47 ± 21.09   431.75 ± 34.46   0.001[\*](#t2f1){ref-type="table-fn"}
                                                        
  MEX SLEDAI          1.31 ± 0.30      3.56 ± 1.41      0.006[\*](#t2f1){ref-type="table-fn"}

Unpaired T Test; p = 0.05.

Discussion {#sec1-4}
==========

This study revealed the efficacy of Seluang fish oil as one of the newest therapeutic approaches to SLE. High level of vitamin D (cholecalciferol) is believed to be the biological plausibility of the efficacy of Seluang fish oil against SLE. Vitamin D is a sterol group compound which is important in the regulation related to the immune system \[[@ref7]\].

Vitamin D is a signalling molecule that activates vitamin D receptors, which are part of intracellular receptors. Activation of the vitamin D receptor will suppress the regulator protein Nuclear Factor-Kappa Beta (NF-kB) gene expression so that NF-kB gene expression process does not occur and hence NF-kB protein is suppressed \[[@ref8]\]. NF-kB is a transcription factor that plays a role in the expression of proinflammatory cytokine genes. NF-kB suppression causes a decrease in IL-2 gene expression and suppression of IL-2 cytokines. The occurrence of suppression of IL-2 causes a decrease in T lymphocyte cell proliferation, which will be followed by a decrease in lymphocyte cell proliferation. IL-2 is believed to play a major role in autoimmune disorders \[[@ref9]\].

Proliferation suppression of lymphocyte cells causes suppression of auto-antibody production of cell components. This decrease in auto-antibody production will cause a decrease in cascade inflammatory activation and thus the pro-inflammatory cytokines, such as IL-1, IL-6 and IL-17 \[[@ref10]\]. Activation of proinflammatory cytokines will cause oxidative stress in cells. Activation of oxidative stress causes caspase cascade activation, which will lead to cell death. Extensive cell death in the organ, causing damage to target organs, such as the kidneys, heart, lungs and blood vessels \[[@ref11]\]. IL-6 is an inflammatory cytokine produced by various cells, such as monocytes, fibroblasts, endothelial cells and B and T lymphocyte cells. These cytokines regulate differentiation of lymphocyte B cells. Differentiation of B cells leads to the initiation of antibody production, Ig G. The increase in IL-6 certainly promotes the production of autoantibodies in SLE patients, which in turn worsens the clinical condition of SLE patients \[[@ref12]\], \[[@ref13]\]. IL-17 is a cytokine produced by lymphocyte T cells, a type of T-helper cell 17. IL-17 is believed to be an important inflammatory cytokine that plays a role in the process of organ destruction in SLE cases. Increased production of IL-2, will cause proliferation of T cells, including T-helper 17 cells \[[@ref14]\], \[[@ref15]\], \[[@ref16]\].

Another study conducted on the SLE mice showed that vitamin D3 supplementation possessed good efficacy in suppressing the inflammatory process. Vitamin D3 suppressed the production of IL-17, IL-23 and gamma interferon. Where an increase in IL-17, IL-23 and gamma interferon would lead to cell damage, especially the kidneys and blood vessels in mice \[[@ref4], [@ref10]\]. The above study certainly supported the results of this study, where high vitamin D contained in Seluang fish oil was believed to play a major role in the efficacy of Seluang fish oil in SLE cases.

In conclusion, Seluang fish oil possessed the efficacy of reducing the inflammatory response in SLE patients by increasing serum vitamin D levels.

**Funding:** This research did not receive any financial support

**Competing Interests:** The authors have declared that no competing interests exist
